Contents:

Table of Contents 1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS Study Reliability and Reporting Limitations Disclaimers Data Interpretation & Reporting Level Quantitative Techniques & Analytics Product Definitions and Scope of Study 2. MARKET OVERVIEW Recession Plummets Global DES Market Current and Future Analysis Regional Analysis Major Issues and Trends Recession Hits Cardiovascular Device Makers Changing Fortunes in the Global DES Industry Global Market Recovers From Safety Issue Shambles Competition Intensifies as New Products Make Way in to the Market Drug-Eluting Stents Transforming the Face of Interventional Cardiology Market Table 1: Global Stents Market by Type (2006-2008): Percentage Breakdown of Value Sales for Drug-Eluting Stents and Bare-Metal Stents (includes corresponding Graph/Chart) Concerns Over Adverse Effects Remain A Major Snag Potential Decline in Hospital Revenues Glaring Lack of Health-Related Initiatives the World Over Bioabsorbable Stents Closer to Reality Than Expected 3. COMPETITIVE LANDSCAPE A Brief Introduction to DES Suitable Patient Types for Drug-Eluting Stents Market Dominated by Small Number of Players Drug-Eluting Stents - Competitive Landscape World Market for Drug-Eluting Stents (2002 - 2010): DES Brands Launched by Major Manufacturers- Cordis, Boston Scientific, Cook Group, Abbott/Guidant, and SMT Boston Scientific Leads Global DES Market, Abbott Closes In Table 2: World Drug Eluting Stents Market (2010): Market Share Breakdown of Value Sales by Leading Players - Boston Scientific, Abbott, Medtronic, and Others (includes corresponding Graph/Chart) J&J Has One Key DES In Pipeline And So Does Abbott Xience and Promus Take the Lead Table 3: World Drug Eluting Stents Market by Leading Brands (2006 - A Peek into the Past): Market Share Breakdown of Value Sales by Leading DES Brands - Cypher, Taxus, and Others (includes corresponding Graph/Chart) Major DES Drugs Available in the Market Sirolimus Paclitaxel Everolimus Zotarolimus Biolimus Other Treatments Available for Treating In-Stent Restenosis Major Drug-Eluting Stent Products in the Market XIENCE V (Abbott) PROMUS® (Boston Scientific) XIENCE PRIME (Abbott) TAXUS® Liberté® Atom™ (Boston Scientific) Endeavor (Medtronics) Cypher (Cordis/Johnson & Johnson) Taxus (Boston Scientific) 4. CORONARY STENTING - AN INSIGHT Cardiovascular Diseases - A Brief Description Table 4: World Market for Cardiovascular Therapies (2006): Percentage Share Breakdown of Value Sales by Product Category-Drug-Eluting Stents, Cardiac Resynchronization Therapy, Cardiac Markers, Portable Automated External Defibrillators, and Angiogenesis/Gene Therapy ($ Millions) (includes corresponding Graph/Chart) Coronary Heart Disease Traditional Methods of Treating Blockage of Coronary Arteries Percutaneous Transluminal Coronary Angioplasty (PTCA) Coronary Artery Bypass Graft (CABG) Restenosis Evolution of Coronary Stents as a Replacement for Traditional Methods What are Coronary Stents? How is Coronary Stenting Performed - Procedure Risks and Problems Associated with Placing a Stent Restenosis Still Pervasive Even after the Use of Stents Market Analysis for Coronary Stents By Types Table 5: World Coronary Stents Market (2005 & 2006): Percentage Share Breakdown of Value Sales by Type- Drug Eluting and Bare Metal Stents By Region/Country Table 6: World Market for Coronary Stents (2006): Percentage Share Breakdown of Value Sales by Region/ Country -US, Japan, Europe, Japan, and Rest of World (includes corresponding Graph/Chart) By Major Players Table 7: World Market for Coronary Stents (All Stents) (2005- 2007- A Recent Past Review): Percentage Share Breakdown of Value Sales by Major Players- Johnson & Johnson, Guidant, Boston Scientific, Medtronic, Abbott, and Others (includes corresponding Graph/Chart) In-Stent Restenosis - Outcome of Bare Metal Stents In-Stent Restenosis - Definition Causes of In-Stent Restenosis 5. COST AND PRICE ECONOMICS Cost Evaluation of DES Initial Procedural Costs Remain High Table 8: Average Price Per DES Unit for the Period 2004-2005 Table 9: Worldwide Average Stent Prices (2002-2005): Breakdown of Regions by Drug Eluting Stents and Bare Metal Stents (includes corresponding Graph/Chart) Follow-Up Costs Provide Relief Table 10: A Comparative Presentation of Long-Term Costs of DES and CABG Conversion of CABG Procedures to DES Impact of DES on Indirect Costs 6. RESEARCH AND DEVELOPMENT INITIATIVES Boston Completes European and Intercontinental Enrollment Phases Medtronic To Start Clinical Study Guidant Accomplishes Patient Enrollment Abbott Receives FDA Approval for Initiation of ZoMaxx Clinical Trials Medtronic Commences Endeavor III Clinical Trial MIV Therapeutics Completes Drug-Eluting Stent Coating R&D Program Guidant Conducts First Implant as Part of Drug Eluting Stent Trial Medtronic’s Endeavor Drug Eluting Stent Shows Positive Results Cypher™ Coronary Stent Trials Show Restenosis Rates Decline by 5.1% Boston Scientific Demonstrates Positive Results for Taxus IV Clinical Trial Medtronic Initiates Endeavor II Clinical Trials for Endeavor Drug Eluting Stent Guidant’s Clinical Trials for Coronary Stent Demonstrates Positive Results 7. CLINICAL TRIALS UNDERTAKEN FROM 2002-2007 MIV Commences Clinical Trials of HC Stent XTNT Voiced CUSTOM III Trial Program of NX™ DES System Dynatek Completes DES Coating Durability Trial STEALTH Trial SIROCCO Trial Cook Trial ZoMAXX Trial Ravel Trial Sirius Trial C - Sirius Trial E - Sirius Trial Taxus I through VI Clinical Trials Other Clinical Trials 8. PRODUCT INNOVATIONS/INTRODUCTIONS NIMS Develops Am80 Drug Eluting Stent Cook Medical Unveils New CE Marked Zilver PTX Drug-Eluting Peripheral Stent Medtronic Rolls Out Driver Sprint RX Coronary Stent System Boston Scientific Launches TAXUS Liberte DES In Japan Medtronic Unveils Endeavor Sprint Drug-Eluting Stent in The US CeloNova Unveils CATANIA™ Stent System with NanoThin Polyzene®-F 9. PRODUCT INNOVATIONS/INTRODUCTIONS IN RECENT PAST - A PERSPECTIVE BUILDER Abbott Launches Xience V Drug-Eluting Coronary Stent in Europe Boston Introduces Taxus(R) Express2(TM) in Japan Cordis Brings Advanced Drug-Eluting Stent Sorin Unveils Enhanced Janus Flex in Europe EUREKA Develops Latest Generation of Drug- Eluting Stent MIV Therapeutics Develops New Drug Eluting Coating Technology in Canada Medtronic to Launch Endeavor DES in Europe DISA Vascular (Pty) Ltd Introduces ChromoFlex in Europe Boston Scientific Introduces Taxus Liberté Drug Eluting Stent in Europe Boston Scientific Introduces Innovative Drug-Eluting Stent, Taxus in the US Market Johnson & Johnson Introduces Drug-Eluting Stent MIV Therapeutics to Introduce Advanced Biocompatible Coatings Guidant Develops Champion Drug-Eluting Stent System University of Virginia Launches Drug-Eluting Stent Implant Sciences and CardioTech Jointly Develop Drug Eluting Stent Boston Scientific Introduces Express™ Stent in the European Market 10. RECENT INDUSTRY ACTIVITY Biosensors Takes Over Cardiomind Tryton Medical Implants First Tryton® in Austria and Portugal Medtronic to Take Over Invatec Abbott Obtains Approval for XIENCE V Stent System in Japan Boston Scientific Obtains Approval for Promus Stent In Japan Opto Circuits (India) Obtains CE Mark Approval for Taxcor Plus Abbott Obtains Approval for Additional Indications of Xience V and Xience Prime Bayer MaterialScience to Acquire PolyBioMed Boston Scientific Obtains Health Canada Approval for PROMUS® Abbott Labs to Introduce XIENCE V Stent in China Abbott Obtains Approval for XIENCE V® from Health Canada Boston Scientific Obtains FDA Approval for TAXUS® Liberte® Atom™ Stent Medtronic Obtains CE Mark Approval for Endeavor DES Biosensors International Group Receives CE Mark Approval for BioMatrix Medtronic Receives Approval for Endeavor Drug-eluting Stent in Japan Boston Scientific Obtains Japanese Approval for TAXUS® Liberte® Atom™ XTENT Receives CE Mark Approval for CUSTOM NX DES Maxcor Lifescience Inks Strategic Cooperation Agreement with Micell Technologies Boston Scientific Snaps Up Labcoat Medtronic Commences PROTECT Comparative Study in US B.Braun to Invest in its India based Operations Medtronic Secures TDP Approval for Endeavor Zotarolimus Eluting Coronary Stent Medtronic Receives US FDA Approval for Endeavor Drug-Eluting Stent Novation and Medtronic Ink National Agreement 11. INDUSTRY ACTIVITY IN RECENT PAST - A PERSPECTIVE BUILDER MIV Therapeutics Acquires Biosync Scientific J & J Acquires Conor Medsystems FDA Approves Boston Scientifis’s Taxus Stent with Extended Shelf Life Lombard Collaborates With S&N India Establishes Asia’s first Catheter and Stent Unit. Abbott Requests FDA Approval for Xience Brookwood and TTV Start Joint Venture SurModics Acquires Brookwood Pharmaceuticals, Inc ARIAD Collaborates with ICON Medical Biosensors Acquires 50% Stake in JWMS Cordis’ Cypher Select™ Plus Receives Approval in Europe Boston Scientific Acquires Guidant for $27 Billion, Abbott Gets Guidant’s Vascular and Cardiac Therapies Businesses as Part of Deal Conor COSTAR II Receives US FDA Approval Abbott Expands Vascular Sites in Ireland Medtronic’s Endeavor® Attains Reimbursement Approval in France SurModics Offers License for Hydrophilic Technology to Devax Conor obtains License for Novartis’ Pimecrolimus Medtronics Makes Final PMA Submission for Endeavor Volcano Collaborates with CRF, Cardialysis and Stanford University Boston’s PROMUS Receives CE Mark Approval SurModics and X-Cell Inks Licensing Agreement Medtronic Receives Regulatory Approval for Endeavor (R) Medtronics’ Endeavor Obtains Chinese Regulatory Approval Biosensors Collaborates with JW Medical Biosensors and Weigao To Consolidate Joint Venture Biotronik Enters Multi-Drug Deal with Novartis MIVT Enters Collaboration Deal with SMT SMT’s Infinnium Paclitaxel System Receives CE Mark Guidant’s Xience V Receives European Approval Medtronic Files Initial PMA Module TO US FDA Boston Scientific Receives European Approval for TAXUS(R) Biosensors Attains US Patent Covering DES Technology MediVas LLC and Estracure Inc Sign Agreement for Development of DES Relisys Medical of India Finalizes Deal with Germany Based Blue Membranes X-cell Medical Enrolls for Clinical Trial of ETHOS I Estradiol Eluting Stent. Biosensors International Group Receives CE Approval for First DES, Axxion Boston Scientific Corp Receives CE Mark Approval for Marketing Larger Stent Sizes Medtronic Receives CE Mark Approval for Commercial Sale of Endeavor DES in Europe Biosensors International Opens New Interventional Cardiology Unit in Singapore Johnson & Johnson Recalls Cypher Drug-Eluting Stents Boston Scientific Buys Out Precision Vascular Systems Implant Sciences and CardioTech International enter into Partnership with CorNova Avantec Vascular Corporation Signs Agreement with Novartis Pharma AG Guidant and Cordis Enter into Promotion Agreement Genvec Collaborates with Cordis Cordis Receives Approval from Japanese Ministry of Health Boston Scientific Modifies Production of Taxus Drug-Eluting Stent Guidant Acquired CE Mark Approval for Multi-Link Bifurcation Stent System Boston Scientific Receives Reimbursement Approval from French Government Boston Scientific Withdraws Consortium of Drug-Coated Stents Boston Scientific’s Taxus Gets FDA Approval Cypher Stent Receives Approval from FDA AVD Acquires the Assets of Jomeds Coronary and Peripheral Business Line Guidant Acquires Biosensors Everolimus Eluting Stent Assets Biosensors Sign Distribution Agreement with Terumo Guidant Obtains the Rights of Polymer Technologies Developed By MediVas Biosensors Pens a Deal with X-Cell to Start Drug-Eluting Stent Company Debiotech Receives Global License to Drug Eluting Stent Technology Boston Scientific Markets Drug-Eluting Stents to Indian Market Hoag Heart First to Receive New Drug-Eluting Stents Abbott Purchases Biocompatibles Cardiovascular Stent Business Guidant Takes Over Cook Group Medtronic Enters into a Co-Exclusive Agreement with Abbott Angiotech Accords with NeoRx for Paclitaxel License Novartis Pharma AG Enters into a Licensing Agreement with Guidant Cordis Declares Positive Results in Bifurcation Feasibility Study PharmaSonics Initiates the Clinical Trials for Intravascular Sonotherapy Guidant Declares Deliver II Clinical Trial Results Clinsights Opens a Drug-Eluting Stent Center Boston Scientific Acquires Global Co-Exclusive Rights from Angiotech Angiotech Pharmaceuticals Elucidates the Conclusions of Taxus I Clinical Trial Boston Scientific Proclaims Zero Restenosis for Taxus Drug- Eluting Stent Trial Boston Scientific Conducts Taxus IISR Clinical Trial 12. FOCUS ON SELECT GLOBAL PLAYERS Abbott Vascular (USA) Angiotech Pharmaceuticals, Inc (Canada) AngioDynamics, Inc. (USA) Boston Scientific, Inc. (USA) Biocompatibles International Plc (UK) Biosensors International Pte Ltd. (Singapore) Cordis Corporation (USA) Medtronic, Inc.(USA) MIV Therapeutics Inc (Canada) SurModics, Inc. (USA) 13. GLOBAL MARKET PERSPECTIVE Table 11: World Recent Past, Current and Future Analysis for Drug-Eluting Stents by Geographic Region - US, Japan, Europe and Rest of the World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2015 (includes corresponding Graph/Chart) Table 12: World Historic Review for Drug-Eluting Stents by Geographic Region - US, Japan, Europe and Rest of the World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart) Table 13: World 11-Year Perspective for Drug-Eluting Stents by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of the World Markets for Years 2005, 2010, & 2015 (includes corresponding Graph/Chart) 14. THE UNITED STATES A.Market Analysis Current and Future Analysis Issues and Trends US Healthcare Ideology The Important Role of Medicaid in the US Drug-Eluting Stents - Competitive Landscape Boston Leads the Market, Even As Taxus Loses Leadership Table 14: US Drug Eluting Stents Market (2009): Market Share Breakdown of Value Sales by Leading Players - Boston Scientific, Abbott, and Johnson & Johnson/Medtronic (includes corresponding Graph/Chart) Drug-Eluting Stents Launched in the US by Major Manufacturers (2003-2009) Select Leading DES Products in the Market Cypher - First to Market Taxus Beats Cypher Regulatory Environment FDA Framework Major Drug-Eluting Stents Approved by FDA FDA Approvals in the Recent Past B.Market Analytics Table 15: US Recent Past, Current and Future Analysis for Drug-Eluting Stents Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2015 (includes corresponding Graph/Chart) Table 16: US Historic Review for Drug-Eluting Stents Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart) 15. JAPAN A.Market Analysis Current and Future Analysis Healthcare System in Japan Table 17: Japanese Market for Drug Eluting Stents (2005-2008): Market Share Breakdown of Sales Revenue by Major Players- Johnson & Johnson Boston Scientific, and Medtronic Table 18: Japanese Market for Stents (2005-2007): Market Share Breakdown of Sales Revenues by Major Players- Abbott/Guidant, Medtronic, Johnson & Johnson, Boston Scientific, and Others (includes corresponding Graph/Chart) B.Market Analytics Table 19: Japanese Recent Past, Current and Future Analysis for Drug-Eluting Stents Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2015 (includes corresponding Graph/Chart) Table 20: Japanese Historic Review for Drug-Eluting Stents Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart) 16. EUROPE A.Market Analysis Current and Future Analysis Regional Analysis Issues and Trends Reimbursement Woes Continue in Europe Reimbursement - A Major Hurdle in European Market Penetration of DES Slow Market Penetration of New Medical Devices in Europe Taxus - Leading the European Stent Market Leading Stent Manufacturers in Europe Table 21: European Market for Stents (2005-2007): Market Share Breakdown of Sales Revenue by Major Players- Abbott/Guidant, Johnson & Johnson, Boston Scientific, Medtronic, and Others (includes corresponding Graph/Chart) Healthcare System in Europe B.Market Analytics Table 22: European Recent Past, Current and Future Analysis for Drug-Eluting Stents by Geographic Region - France, Germany, Italy, UK, Spain and Rest of the World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2015 (includes corresponding Graph/Chart) (includes corresponding Graph/Chart) Table 23: European Historic Review for Drug-Eluting Stents by Geographic Region - France, Germany, Italy, UK, Spain and Rest of the Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart) Table 24: European 11-Year Perspective for Drug-Eluting Stents by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain and Rest of Europe Markets for Years 2005, 2010 and 2015 (includes corresponding Graph/Chart) 16a. FRANCE A.Market Analysis Healthcare System in France Current and Future Analysis B.Market Analytics Table 25: French Recent Past, Current and Future Analysis for Drug-Eluting Stents Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2015 (includes corresponding Graph/Chart) Table 26: French Historic Review for Drug-Eluting Stents Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart) 16b. GERMANY A.Market Analysis Healthcare Policies in Germany Lower Market Penetration of DES B.Market Analytics Table 27: German Recent Past, Current and Future Analysis for Drug-Eluting Stents Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2015 (includes corresponding Graph/Chart) Table 28: German Historic Review for Drug-Eluting Stents Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart) 16c. ITALY A.Market Analysis Current and Future Analysis Italian Healthcare System Local Healthcare Agencies National Health System in Italy B.Market Analytics Table 29: Italian Recent Past, Current and Future Analysis for Drug-Eluting Stents Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2015 (includes corresponding Graph/Chart) Table 30: Italian Historic Review for Drug-Eluting Stents Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart) 16d. THE UNITED KINGDOM A.Market Analysis Current and Future Analysis National Health System in the UK B.Market Analytics Table 31: UK Recent Past, Current and Future Analysis for Drug-Eluting Stents Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2015 (includes corresponding Graph/Chart) Table 32: UK Historic Review for Drug-Eluting Stents Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart) 16e. SPAIN A.Market Analysis Current and Future Analysis Healthcare System in Spain B.Market Analytics Table 33: Spanish Recent Past, Current and Future Analysis for Drug-Eluting Stents Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2015 (includes corresponding Graph/Chart) Table 34: Spanish Historic Review for Drug-Eluting Stents Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart) 16f. REST OF EUROPE A.Market Analysis Current and Future Analysis B.Market Analytics Table 35: Rest of Europe Recent Past, Current and Future Analysis for Drug-Eluting Stents Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2015 (includes corresponding Graph/Chart) Table 36: Rest of Europe Historic Review for Drug-Eluting Stents Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart) 17. REST OF WORLD A.Market Analysis Current and Future Analysis Chinese Drug-Eluting Stents Market Witnesses Robust Growth B.Market Analytics Table 37: Rest of the World Recent Past, Current and Future Analysis for Drug-Eluting Stents Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2015 (includes corresponding Graph/Chart) Table 38: Rest of World Historic Review for Drug-Eluting Stents Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart) COMPETITIVE LANDSCAPE Total Companies Profiled: 39 (including Divisions/Subsidiaries - 46) --------- Region/Country Players --------- The United States 26 Canada 3 Japan 1 Europe 11 Germany 2 The United Kingdom 3 Italy 1 Rest of Europe 5 Asia-Pacific (Excluding Japan) 4 Africa 1 ---------

Companies Mentioned

The Companies Mentioned inside the Report include: Abbott Laboratories (USA) Cardiosynopsis, Inc (USA) CardioTech International, Inc (USA) Carmeda A B (Sweden) Conor Medsystems, Inc (USA) Cook Group, Inc (USA) Cornova, Inc (USA) Debiotech SA (Switzerland) Disa Vascular (PTY) Ltd (South Africa) Endologix, Inc (USA) GenVec, Inc (USA) Guidant Corporation (USA) Cordis Corporation (USA) MediVas LLC (USA) Medtronic, Inc (USA) MIV Therapeutics, Inc (Canada) Neorx Corporation (USA) Novoste Corporation (USA) Occam International BV (The Netherlands) Pharmaceutical Product Development, Inc (USA) PharmaSonics, Inc (USA) Sorin Group SpA (Italy) SurModics, Inc (USA) X-Cell Medical, Inc (USA)